For US Healthcare Professionals Only
Indolent ISMAdvanced SMPDGFRA GIST
  Impact of ISM   
About ISMBurden of ISM
  About AYVAKIT  
  Efficacy   
PIONEER Study DesignEfficacy

  Safety  
  Dosing  
  Patient Perspectives   
Patient StoriesPatient Profiles
  Resources   
Access and SupportPractice ResourcesPatient ResourcesFAQsConnect with UsSM Peer Directory
Indolent ISMAdvanced SMPDGFRA GIST

ACCESS AND SUPPORT

YourBlueprint® provides dedicated, personalized support to help your patients from Day 1

YourBlueprint is a patient support program designed with your patients in mind. YourBlueprint provides a variety of support to eligible patients throughout many aspects along the treatment journey.

  • Co-pay Support
  • Coverage Interruption
  • QuickStart
  • Patient Assistance Program
  • Case Managers can also help your patients through nonclinical aspects of therapy by providing 1:1 support calls and patient education resources

AYVAKIT has broad national coverage

99 percent

Over 99% of commercial insurance plans and 99% of Medicare plans cover AYVAKIT*

*Data on coverage are as of December 2024.

Co-pay Assistance Program

$0

Approximately 90% of patients with commercial insurance paid $0 per month† with help from their insurance and with the YourBlueprint® Co-Pay Card‡ when they accessed AYVAKIT through our network of specialty pharmacies.§

†Data on co-pay assistance are as of December 2024. Cost-sharing data are for those patients with commercial insurance.

‡Up to an annual maximum benefit of $25,000. Terms and conditions apply.

§This program covers co-pay, co-insurance and deductible expenses for those who qualify.

YourBlueprint® logo
Enroll your patients at the time of prescription to support the patient experience and access to programs
Enroll your patientExternal LinkEligibility criteria may apply.

AYVAKIT will require a prior authorization with
the enrollment form

Most denials for AYVAKIT are due to missing or incomplete information. When working on insurance coverage approval for AYVAKIT, YourBlueprint and our network of specialty pharmacies can help support your patient through the process of managing a prior authorization requirement.

AYVAKIT prior authorization requirements with the enrollment form:

Stethoscope

Diagnosis codes

Test tubes

Lab results
(platelet counts, per label)

Clinical notes

Clinic notes with
SM subtype

Access and Support Resources

YourBlueprint Program Overview for HCPs

A high-level overview of the YourBlueprint patient support program for HCPs.

Download Program Overview

Access and Coverage Flashcard

A resource showing the cost and coverage information on AYVAKIT.

Download the FlashcardDownload Link

HCP=healthcare provider; SM=systemic mastocytosis.



Looking for additional resources for your practice and patients?
PRACTICE RESOURCESicon arrowPATIENT RESOURCESicon arrow

Patient portrayal

Expand +
INDICATION

AYVAKIT® (avapritinib) is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).

Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of <50 x 109/L.

IMPORTANT SAFETY INFORMATION
INDICATION & IMPORTANT SAFETY INFORMATION

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC; <1% were Grade 3. Depending on the severity, withhold AYVAKIT and then resume at the same dose, or permanently discontinue AYVAKIT.

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective contraception during treatment with AYVAKIT and for 6 weeks after the final dose. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks following the final dose.

Adverse Reactions—The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors or inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤20 mcg unless a higher dose is necessary.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here to see the full Prescribing Information for AYVAKIT.

References:

  1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; November 2024.
  2. Kristensen T et al. Am J Hematol. 2014;89(5):493-498.
  3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372.
  4. Ungerstedt J et al. Cancers. 2022;14(16):3942.
  5. Pardanani A. Am J Hematol. 2023;98(7):1097-1116.
  6. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2023.
  7. Gülen T et al. J Intern Med. 2016;279(3):211-228.
  8. Theoharides TC et al. N Engl J Med. 2015;373(2):163-172.
  9. Gotlib J et al. NEJM Evidence. 2023;2(6). Published online May 23, 2023. doi:10.1056/EVIDoa2200339
  10. Gilreath JA et al. Clin Pharmacol. 2019;11:77-92.
  11. Evans EK et al. Sci Transl Med. 2017;9(414):eaao1690.
  12. Padilla B et al. Orphanet J Rare Dis. 2021;16(1):434.
  13. van Anrooij B et al. Allergy. 2016;71(11):1585-1593.
  14. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited April 24, 2024]. (WHO Classification of Tumours Series, 5th ed.; vol. 11). Available from: https://tumourclassification.iarc.who.int/chapters/63
  15. Dranitsaris G et al. J Oncol Pharm Pract. Published online December 27, 2023. doi:10.1177/10781552231221149
  16. Siebenhaar F et al. Immunol Allergy Clin North Am. 2014;34(2):433-447.
  17. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
  18. Akin C, ed. Mastocytosis: A Comprehensive Guide. Springer; 2020.